Sánchez-Serrano AP, Espino SS, Aurora Ramírez-Torres A

Language: Spanish
References: 17
Page: 221-227
PDF size: 316.81 Kb.

ABSTRACT

The most frequent late onset congenital adrenal hyperplasia (LOCAH) form is the 21-hydroxylase enzyme deficiency with a variable clinical presentation depending on the degree of the enzymatic deficiency. Women with this condition can suffer from gonadal dysfunction including amenorrhea, anovulation, infertility and hyperandrogenism similar to those patients with polycystic ovary syndrome (PCOS).
Objective: To describe and analyze the LOCAH prevalence at the National Institute of Perinatology according to the high levels of 17 alpha-hydroxiprogesterone (17OHP) and the clinical and biochemical differences of these patients of those with PCOS.
Methods: We reviewed clinical files from patients with high serum 17 alpha-hidroxiprogesterone (› 4.0 ng/ mL) from June 2003 to June 2008, we identified those with LOCAH and compare them with patients PCOS patients. We used descriptive statistics, t Student test, U of Mann-Whitney and chi Square test considering significant differences when p was below 0.05.
Results: We selected 147 patients for the analysis. LOCAH was diagnosed in 22 (14.9%) and PCOS in 43 (29.2%), the groups differ in the presence of hirsutism and clitoris hypertrophy. After diagnosis and accurate treatment, patients with LOCAH, presented more successful pregnancies than PCOS group.
Conclusions: The LOCAH prevalence among this group of patients who came from the infertility service is 14.9%. LOCAH patients differ clinically, by lab tests and clinical response to treatment sooner and with better results (ovulation and pregnancy) than PCOS patients.

REFERENCES

1. New MI, Lorenzen F, Pang S, Gunczler P, Dupont B, Levine LS. “Acquired” adrenal hyperplasia with 21-hydroxylase deficiency is not the same genetic disorders as congenital adrenal hyperplasia. J Clin Endocrinol Metab 1979; 48: 356-9.

2. White P, Speiser P. Congenital adrenal hyperplasia due to 21-hydroxilase deficiency. Endocrine Reviews 2000; 21: 245-91.

3. Speiser P, Knochenhauer E, Dewailly D, Fruzzetti F, Marcondes J, Azziz R. A multicenter study of women with nonclassical congenital hyperplasia: relationship between genotype and phenotype. Mol Gen Metabol 2000; 71: 527-34.

4. Azziz R, Hincapié LA, Knochenhauer E. Screening for 21-hydroxilase deficient nonclassical congenital hyperplasia among hyperandrogenic women: a prospective study. Fertil Steril 1999; 72: 915-25.

5. New M. Infertility and androgen excess in nonclassical 21-hydroxylase deficiency. Symposium on the ovary: regulation, dysfunction and treatment, Marco Island, FL. 1996: 195-8.

6. Speiser PW, White PC. Congenital adrenal hyperplasia. N Engl J Med 2008; 349: 776-88.

7. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004; 81: 19-25.

8. Speiser PW, Dupont B, Rubinstein P, Piazza A, Kastelan A, New MI. High frequency of nonclassical steroid 21-hydroxylase deficiency. Am J Hum Genet 1985; 37: 650-7.

9. New MI. Nonclassical 21-hidroxylase deficiency. J Clin Endocrinol Metab 2006; 91: 4205-14.

10. Zerah M, Ueshiba H, Wood E, Speiser PW, Crawford C, McDonald T, Pareira J, Gruen D, New MI. Prevalence of nonclassical steroid 21-hydroxylase deficiency based on a morning salivary 17-hydroxyprogesterone screening test: a small sample study. J Clin Endocrinol Metab 1990; 70: 1662-7.

11. Escobar-Morreale H, Sanchon R, San Millán J. A prospective study of the prevalence of nonclassical congenital adrenal hyperplasia among women presenting with hyperandrogenic symptoms and signs. J Clin Endocrinol Metab 2008; 93: 527-33.

12. Dewailly D. Nonclassic 21-hydroxilase deficiency. Sem Reprod Med 2002; 20: 243-8.

13. Moran C, Azziz R. 21-hydroxilase-defficient nonclassic adrenal hyperplasia: the great pretender. Sem Reprod Med 2003; 21: 295-300.

14. Stikkelbroeck N, Hermus A, Braat D, Otten B. Fertility in women with congenital adrenal hyperplasia due to 21-hydroxylase defficiency. Obstet Gynecol Surv 2003; 58: 275-84.

15. Feldman S, Billaud L, Thalabard JC. Fertility in women with late-onset adrenal hyperplasia due to 21-hydroxilase deficiency. J Clin Endocrinol Metab 1992; 74: 635-9.

16. Hagenfeldt K, Janson P, Holmdahl G, Falhammar H, Filipsson H, Frisén M, Thorén M, Nordenskjöld A. Fertility and pregnancy outcome in women with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Hum Reprod 2004; 23: 1607-13.

17. Falhmmar H, Thorén M, Hagenfeldt K. A 31-year old women with infertility and polycystic ovaries was diagnosed with nonclassical congenital hyperplasia due to a novel mutation in CYP21 gene. J Endocrin Invest 2008; 31: 176-80.